| Name | (2-decoxy-3-dodecylsulfanylpropyl) [(2R,3S,5R)-3-fluoro-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methyl hydrogen phosphate |
|---|---|
| Synonyms |
Fosalvudine tidoxil
Fosalvudine HDP 99.0003 |
| Description | Fosalvudine tidoxil is an orally active nucleoside reverse transcriptase inhibitor (NRTI). Fosalvudine tidoxil is a prodrug derived from Alovudine (HY-B1516). Fosalvudine tidoxil is less toxic than Alovudine and can be used for the research of HIV-1 infection[1]. |
|---|---|
| Related Catalog | |
| Target |
Nucleoside reverse transcriptase[1] |
| In Vivo | Fosalvudine tidoxil (15-100 mg/kg/day; oral; 8 weeks) 对大鼠产生显著的线粒体肝毒性[1]。 Animal Model: Sprague-Dawley rats[1] Dosage: 15, 40, or 100 mg/kg/day Administration: Oral gavage, 8 weeks Result: Induced significant mtDNA depletion. At doses of 15, 40, and 100 mg/kg, the mean hepatic mtDNA values were 62, 64, and 47% of control values, respectively. |
| References |
| Molecular Formula | C35H64FN2O8PS |
|---|---|
| Molecular Weight | 722.93 |
| Exact Mass | 722.41100 |
| PSA | 164.19000 |
| LogP | 8.78420 |